MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
about
MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysisAnalyzing association of the XRCC3 gene polymorphism with ovarian cancer risk.Association between murine double minute 2 T309G polymorphism and risk of liver cancer.The MDM2 309T>G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls.SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers.Negative selection maintains transcription factor binding motifs in human cancer.Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls.Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-AnalysisGenetic variants and mutations of PPM1D control the response to DNA damage.MDM2 rs2279744 polymorphism and endometrial cancer: a meta-analysis.Polymorphisms in the MDM2 gene and risk of malignant bone tumors: a meta-analysis.Analyze association of the progesterone receptor gene polymorphism PROGINS with ovarian cancer risk.MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects.Ewing Sarcoma: influence of TP53 Arg72Pro and MDM2 T309G SNPs.Quantitative assessment of the association between HDMX polymorphism and sarcoma.MDM2 SNP309 is an ethnicity-dependent risk factor for digestive tract cancers.Association of rs2279744 and rs117039649 promoter polymorphism with the risk of gynecological cancer: A meta-analysis of case-control studies.
P2860
Q33643505-761E9E32-3399-499C-8950-F96A5F032797Q33810401-DA60A9E6-617C-44DB-9921-B0C0F6F0CB83Q34433411-75A84CCF-CF43-46E4-831E-AD66E68F8D1DQ34575963-9618F430-DFE4-4D80-B944-933050FC6F9AQ35751762-BCD4C258-08CC-4BA4-A5DC-A88E903CF1EEQ36064184-F88D2A06-3850-4CE7-8F21-7B7ABE69B8E2Q36109482-09952F4E-E4E2-452C-83F2-E1FEF87B3CA5Q37059477-19058C8B-31CD-4FE9-AFFE-C54F08D8C94BQ37205283-6C4981EF-5634-42CA-8648-909C73955614Q37396919-EB1A6881-911E-44F8-BB90-C17A1AB1C9A5Q43679610-8447185F-E901-4A1C-A9B4-1D847F01DC29Q44820188-4B191A88-6A9F-458C-8856-0C1A67AC9071Q45231714-BFDA573B-510A-4529-BF7A-3165F1250337Q47799677-48134FEE-D63E-4FC7-BDAB-28F114D10D40Q51006023-D4560898-DDC2-41C3-8746-523D994C4D68Q53147977-6950A477-9EAD-46CB-BAA4-55D01D6F0B6EQ54439530-EA8A948A-5E96-45C1-B0AC-7B0C1ACA07D9Q54959231-568F4239-D6AD-4D04-A8DE-B53A693268DF
P2860
MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
@en
MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
@nl
type
label
MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
@en
MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
@nl
prefLabel
MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
@en
MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
@nl
P2093
P2860
P1433
P1476
MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
@en
P2093
Beihua Kong
Hongjin Zhao
Linjuan Huang
Qifeng Yang
P2860
P2888
P356
10.1007/S13577-011-0013-4
P577
2011-03-04T00:00:00Z